Donald P Bottaro

List of Publications by Year in Descending Order

160 papers	13,325 citations	53 h-index	114 g-index
208 ext. papers	14,530 ext. citations	7.1 avg, IF	5.68 L-index

#	Paper	IF	Citations
160	Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. *Investigational New Drugs*, **2021**, 39, 1577-1586	4.3	0
159	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. *PLoS ONE*, **2021**, 16, e0241766	3.7	2
158	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. *Clinical Cancer Research*, **2021**, 27, 1391-1398	12.9	7
157	Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.. *Journal of Clinical Oncology*, **2021**, 39, 3-3	2.2	4
156	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 1099-1109	21.7	31
155	Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).. *Journal of Clinical Oncology*, **2020**, 38, 5039-5039	2.2	2
154	Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.. *Journal of Clinical Oncology*, **2020**, 38, 5037-5037	2.2	1
153	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. *Journal of Clinical Oncology*, **2020**, 38, 3672-3684	2.2	37
152	Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. *Cancer Research*, **2020**, 80, 304-318	10.1	37
151	Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors.. *Journal of Clinical Oncology*, **2019**, 37, 3131-3131	2.2	1
150	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).. *Journal of Clinical Oncology*, **2019**, 37, 379-379	2.2	
149	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).. *Journal of Clinical Oncology*, **2019**, 37, 4555-4555	2.2	
148	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, 1-6	3.3	28
147	Met Signaling in Carcinogenesis **2019**, 271-282		
146	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5	10.6	295
145	Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. *Molecular Cancer Therapeutics*, **2018**, 17, 698-709	6.1	7
144	Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. *PLoS ONE*, **2018**, 13, e0199361	3.7	7

143	Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).. *Journal of Clinical Oncology*, **2018**, 36, 4528-4528	2.2	9
142	Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.. *Journal of Clinical Oncology*, **2018**, 36, 515-515	2.2	42
141	Hepatocyte growth factor/MET in cancer progression and biomarker discovery. *Cancer Science*, **2017**, 108, 296-307	6.9	128
140	Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. *Annals of Oncology*, **2017**, 28, v295	10.3	20
139	Targeting the hepatocyte growth factor/Met pathway in cancer. *Biochemical Society Transactions*, **2017**, 45, 855-870	5.1	39
138	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. *Clinical Cancer Research*, **2017**, 23, 2405-2413	12.9	31
137	A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.. *Journal of Clinical Oncology*, **2017**, 35, 4562-4562	2.2	14
136	A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. *Journal of Clinical Oncology*, **2017**, 35, 293-293	2.2	12
135	Effective implementation of novel MET pharmacodynamic assays in translational studies. *Annals of Translational Medicine*, **2017**, 5, 3	3.2	5
134	A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. *Annals of Oncology*, **2016**, 27, vi266	10.3	10
133	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. *Cell Reports*, **2016**, 14, 2476-89	10.6	228
132	The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation. *Cellular Signalling*, **2016**, 28, 1114-23	4.9	4
131	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 135-45	59.2	753
130	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. *Journal of Clinical Oncology*, **2016**, 34, 4534-4534	2.2	7
129	Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells. *PLoS ONE*, **2016**, 11, e0148075	3.7	3
128	Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. *PLoS ONE*, **2016**, 11, e0157130	3.7	5
127	Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, 2553-2553	2.2	1
126	MET Inhibition in Clear Cell Renal Cell Carcinoma. *Journal of Cancer*, **2016**, 7, 1205-14	4.5	16

125	Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. *Clinical Cancer Research*, **2016**, 22, 3683-94	12.9	25
124	A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC). *Annals of Oncology*, **2016**, 27, vi272	10.3	2
123	Expression array analysis of the hepatocyte growth factor invasive program. *Clinical and Experimental Metastasis*, **2015**, 32, 659-76	4.7	3
122	Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide. *Molecular Imaging*, **2015**, 14, 7290.2015.00023	3.7	5
121	Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide. *Molecular Imaging*, **2015**, 14, 499-515	3.7	3
120	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma **2015**, 303-318		
119	Signaling by Met and related receptor tyrosine kinases in urothelial carcinoma of the bladder.. *Journal of Clinical Oncology*, **2015**, 33, e15511-e15511	2.2	
118	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. *Journal of Clinical Oncology*, **2015**, 33, 4521-4521	2.2	1
117	Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist. *Leukemia*, **2014**, 28, 948-51	10.7	3
116	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. *Nature Reviews Urology*, **2014**, 11, 465-75	5.5	169
115	Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. *PLoS ONE*, **2014**, 9, e100586	3.7	44
114	Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. *Journal of Translational Medicine*, **2014**, 12, 199	8.5	12
113	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. *Cancers*, **2014**, 6, 2313-29	6.6	11
112	Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. *Journal of Biological Chemistry*, **2014**, 289, 20448-61	5.4	22
111	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 4501-4501	2.2	21
110	Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue.. *Journal of Clinical Oncology*, **2014**, 32, 16-16	2.2	1
109	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. *Journal of Clinical Oncology*, **2014**, 32, 307-307	2.2	4
108	Met signaling in urothelial carcinoma of the bladder.. *Journal of Clinical Oncology*, **2014**, 32, 4551-4551	2.2	

107	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *Journal of Clinical Oncology*, **2013**, 31, 181-6	2.2	336
106	Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. *PLoS ONE*, **2013**, 8, e54014	3.7	148
105	A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, TPS4589-TPS4589	2.2	2
104	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. *Journal of Clinical Oncology*, **2013**, 31, 314-314	2.2	6
103	Developing a molecular imaging agent for Met using onartuzumab (MetMAb).. *Journal of Clinical Oncology*, **2013**, 31, 11083-11083	2.2	
102	Application of MET pharmacodynamic assays to compare effectiveness of five MET inhibitors to engage target in tumor tissue.. *Journal of Clinical Oncology*, **2013**, 31, 11103-11103	2.2	1
101	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. *Journal of Clinical Oncology*, **2013**, 31, 4543-4543	2.2	1
100	Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. *Cancer Cell*, **2012**, 22, 250-62	24.3	38
99	448 CHARACTERIZATION OF THE AKT-MTOR PATHWAY IN TFE3-FUSION RENAL CELL CANCERS AND IMPLICATIONS FOR TARGETED THERAPY. *Journal of Urology*, **2012**, 187,	2.5	2
98	Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. *Journal of Natural Products*, **2012**, 75, 1632-6	4.9	12
97	Targeting the HGF/Met signaling pathway in cancer therapy. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 553-72	6.4	162
96	Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. *Journal of Nuclear Medicine*, **2012**, 53, 1592-600	8.9	44
95	A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.. *Journal of Clinical Oncology*, **2012**, 30, 355-355	2.2	6
94	Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. *Journal of Clinical Oncology*, **2012**, 30, 372-372	2.2	6
93	Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. *PLoS ONE*, **2012**, 7, e42717	3.7	37
92	A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. *Chemical and Pharmaceutical Bulletin*, **2011**, 59, 1178-9	1.9	25
91	Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides. *Biopolymers*, **2011**, 96, 780-82	2.2	9
90	Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2113-5	2.9	16

89	Development and validation of biomarker assays to assess pharmacodynamic modulation of MET.. *Journal of Clinical Oncology*, **2011**, 29, 3042-3042	2.2	3
88	The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. *Current Signal Transduction Therapy*, **2011**, 6, 146-151	0.8	18
87	A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2010**, 299, L905-14	5.8	6
86	Molecular diagnosis and therapy of kidney cancer. *Annual Review of Medicine*, **2010**, 61, 329-43	17.4	135
85	Targeting the HGF/Met signalling pathway in cancer. *European Journal of Cancer*, **2010**, 46, 1260-70	7.5	164
84	Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells. *Journal of Cellular Biochemistry*, **2010**, 111, 310-21	4.7	13
83	Targeting the Met signaling pathway in renal cancer. *Expert Review of Anticancer Therapy*, **2009**, 9, 785-93	3.5	60
82	Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. *Clinical Cancer Research*, **2009**, 15, 4292-8	12.9	40
81	Hereditary kidney cancer: unique opportunity for disease-based therapy. *Cancer*, **2009**, 115, 2252-61	6.4	89
80	Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids. *Journal of Medicinal Chemistry*, **2009**, 52, 1612-8	8.3	8
79	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. *International Journal of Biochemistry and Cell Biology*, **2009**, 41, 753-6	5.6	43
78	Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. *Journal of Medicinal Chemistry*, **2009**, 52, 943-51	8.3	54
77	Abstract A8: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors **2009**,		3
76	Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients **2009**,		2
75	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma **2009**, 321-334		
74	Grb2 signaling in cell motility and cancer. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 1021-33	6.4	126
73	Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist. *Journal of Medicinal Chemistry*, **2008**, 51, 7459-68	8.3	9
72	Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. *European Urology*, **2008**, 54, 845-53	10.2	10

71	Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2 **2008**, 181-191		
70	Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. *Clinical Cancer Research*, **2007**, 13, 671s-679s	12.9	113
69	Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. *Cancer Research*, **2007**, 67, 6012-6	10.1	38
68	Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. *Clinical Cancer Research*, **2007**, 13, 4660-3	12.9	6
67	Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. *Organic and Biomolecular Chemistry*, **2007**, 5, 367-72	3.9	7
66	Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. *Cell Cycle*, **2006**, 5, 2839-41	4.7	17
65	c-Met ectodomain shedding rate correlates with malignant potential. *Clinical Cancer Research*, **2006** , 12, 4154-62	12.9	64
64	Targeting the c-Met signaling pathway in cancer. *Clinical Cancer Research*, **2006**, 12, 3657-60	12.9	373
63	The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14531-6	11.5	92
62	Synthesis and Use of C-terminally Biotinylated Peptidomimetics with High Grb2 SH2 Domain-binding Affinity **2006**, 208-209		
61	Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. *Anti-Cancer Drugs*, **2006**, 17, 13-20	2.4	54
60	Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. *Journal of Medicinal Chemistry*, **2005**, 48, 3945-8	8.3	22
59	Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1385-8	2.9	12
58	Multifocal renal cancer: genetic basis and its medical relevance. *Clinical Cancer Research*, **2005**, 11, 7206-8	12.9	7
57	Hereditary papillary renal carcinoma type I. *Current Molecular Medicine*, **2004**, 4, 855-68	2.5	77
56	0.2 T magnetic field inhibits angiogenesis in chick embryo chorioallantoic membrane. *Bioelectromagnetics*, **2004**, 25, 390-6	1.6	37
55	Genetic basis of cancer of the kidney: disease-specific approaches to therapy. *Clinical Cancer Research*, **2004**, 10, 6282S-9S	12.9	159
54	Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. *Molecular Cancer Therapeutics*, **2004**, 3, 1289-99	6.1	24

53	Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. *Oncogene*, **2002**, 21, 2201-11	9.2	9
52	Molecular signaling in bioengineered tissue microenvironments. *Annals of the New York Academy of Sciences*, **2002**, 961, 143-53	6.5	76
51	The role of extracellular matrix heparan sulfate glycosaminoglycan in the activation of growth factor signaling pathways. *Annals of the New York Academy of Sciences*, **2002**, 961, 158	6.5	5
50	Control of recombinant human endostatin production in fed-batch cultures of Pichia pastoris using the methanol feeding rate. *Biotechnology Letters*, **2002**, 24, 1631-1635	3	4
49	Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. *FASEB Journal*, **2002**, 16, 950-62	0.9	151
48	Direct application of keratinocyte growth factor, basic fibroblast growth factor and transforming growth factor-alpha during healing of tympanic membrane perforation in glucocorticoid-treated rats. *Acta Oto-Laryngologica*, **2002**, 122, 468-73	1.6	18
47	Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. *Blood*, **2002**, 100, 982-90	9.2	112
46	Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade. *Arthritis and Rheumatism*, **2001**, 44, 73-84		44
45	Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. *Journal of Biological Chemistry*, **2001**, 276, 14308-14	5.4	78
44	Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. *Journal of Biological Chemistry*, **2001**, 276, 32977-83	5.4	78
43	Engineered Extracellular Matrices: A Biological Solution for Tissue Repair, Regeneration, and Replacement **2001**, 2, 9-12		2
42	Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. *Oncogene*, **2000**, 19, 640-8	9.2	29
41	Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases. *Oncogene*, **2000**, 19, 2846-54	9.2	25
40	Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. *Molecular and Cellular Biology*, **2000**, 20, 2055-65	4.8	54
39	Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. *Journal of Biological Chemistry*, **2000**, 275, 4374-82	5.4	296
38	A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation. *Peptides*, **2000**, 21, 1449-56	3.8	25
37	Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. *Journal of Biological Chemistry*, **1999**, 274, 19465-72	5.4	209
36	Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. *Oncogene*, **1999**, 18, 3399-406	9.2	78

35	Identification and dynamics of a heparin-binding site in hepatocyte growth factor. *Biochemistry*, **1999**, 38, 14793-802	3.2	53
34	Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. *Biochemistry*, **1999**, 38, 1765-71	3.2	44
33	The acidic domain and first immunoglobulin-like loop of fibroblast growth factor receptor 2 modulate downstream signaling through glycosaminoglycan modification. *Molecular and Cellular Biology*, **1999**, 19, 6754-64	4.8	12
32	Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor. *Oncogene*, **1998**, 17, 481-92	9.2	22
31	The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site. *Structure*, **1998**, 6, 109-16	5.2	54
30	Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. *Genes and Development*, **1998**, 12, 1587-92	12.6	236
29	Colocalization of heparin and receptor binding sites on keratinocyte growth factor. *Biochemistry*, **1998**, 37, 8853-62	3.2	14
28	Identification of serine 643 of protein kinase C-delta as an important autophosphorylation site for its enzymatic activity. *Journal of Biological Chemistry*, **1997**, 272, 24550-5	5.4	59
27	Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. *Biochemical Journal*, **1997**, 326 (Pt 3), 763-72	3.8	48
26	A novel human ERK phosphatase regulates H-ras and v-raf signal transduction. *Oncogene*, **1997**, 14, 2633-39	9.2	39
25	Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. *EMBO Journal*, **1997**, 16, 5608-17	13	89
24	Peptides derived from the interferon-induced PKR prevent activation by HIV-1 TAR RNA. *Virology*, **1996**, 222, 193-200	3.6	14
23	Microtubule dynamic turnover is suppressed during polarization and stimulated in hepatocyte growth factor scattered Madin-Darby canine kidney epithelial cells. *Cytoskeleton*, **1996**, 35, 225-36		17
22	Identification of tyrosine 187 as a protein kinase C-delta phosphorylation site. *Journal of Biological Chemistry*, **1996**, 271, 26404-9	5.4	54
21	Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. *Journal of Biological Chemistry*, **1996**, 271, 13110-5	5.4	103
20	Human dual specificity phosphatase VHR activates maturation promotion factor and triggers meiotic maturation in Xenopus oocytes. *Journal of Biological Chemistry*, **1995**, 270, 14229-34	5.4	15
19	Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. *Science*, **1995**, 267, 381-3	33.3	761
18	Keratinocyte growth factor. *Cell Biology International*, **1995**, 19, 399-411	4.5	211

17	High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 989-93	11.5	69
16	Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 7144-8	11.5	103
15	Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1993**, 1155, 357-71	11.2	108
14	Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 246-50	11.5	670
13	Expression cloning of a human dual-specificity phosphatase. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 12170-4	11.5	177
12	A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 415-9	11.5	470
11	Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. *Science*, **1991**, 251, 72-5	33.3	408
10	Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*, **1991**, 251, 802-4	33.3	2046
9	Identification of a competitive HGF antagonist encoded by an alternative transcript. *Science*, **1991**, 254, 1382-5	33.3	201
8	Keratinocyte growth factor. A fibroblast growth factor family member with unusual target cell specificity. *Annals of the New York Academy of Sciences*, **1991**, 638, 62-77	6.5	131
7	PDGF induction of tyrosine phosphorylation of GTPase activating protein. *Nature*, **1989**, 342, 711-4	50.4	478
6	The 18 kDa cytosolic acid phosphatase from bovine live has phosphotyrosine phosphatase activity on the autophosphorylated epidermal growth factor receptor. *FEBS Letters*, **1989**, 250, 469-73	3.8	72
5	The American Microcirculatory Society Landis Award lecture. Endothelial cells, inflammatory edema, and the microvascular barrier: comments by a "free radical". *Microvascular Research*, **1988**, 35, 246-64	3.7	15
4	Serotonin, norepinephrine, and histamine mediation of endothelial cell barrier function in vitro. *Journal of Cellular Physiology*, **1986**, 128, 189-94	7	66
3	Heterogeneity of intimal and microvessel endothelial cell barriers in vitro. *Microvascular Research*, **1986**, 32, 389-98	3.7	41
2	Hepatocyte growth factor/Met signaling in cancer204-217		
1	Targeting HGF with Antibodies as an Anti-Cancer Therapeutic Strategy155-198		